[go: up one dir, main page]

EP1292334A4 - Proteine de fusion bispecifique et son procede d'utilisation permettant d'ameliorer l'action tueuse de cellules effectives sur des cellules cibles - Google Patents

Proteine de fusion bispecifique et son procede d'utilisation permettant d'ameliorer l'action tueuse de cellules effectives sur des cellules cibles

Info

Publication number
EP1292334A4
EP1292334A4 EP01939954A EP01939954A EP1292334A4 EP 1292334 A4 EP1292334 A4 EP 1292334A4 EP 01939954 A EP01939954 A EP 01939954A EP 01939954 A EP01939954 A EP 01939954A EP 1292334 A4 EP1292334 A4 EP 1292334A4
Authority
EP
European Patent Office
Prior art keywords
fusion protein
target cells
effector cell
cell killing
bispecific fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01939954A
Other languages
German (de)
English (en)
Other versions
EP1292334A1 (fr
Inventor
Nabil Hanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of EP1292334A1 publication Critical patent/EP1292334A1/fr
Publication of EP1292334A4 publication Critical patent/EP1292334A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01939954A 2000-06-22 2001-06-04 Proteine de fusion bispecifique et son procede d'utilisation permettant d'ameliorer l'action tueuse de cellules effectives sur des cellules cibles Withdrawn EP1292334A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21325200P 2000-06-22 2000-06-22
US213252P 2000-06-22
PCT/US2001/040835 WO2001097844A1 (fr) 2000-06-22 2001-06-04 Proteine de fusion bispecifique et son procede d'utilisation permettant d'ameliorer l'action tueuse de cellules effectives sur des cellules cibles

Publications (2)

Publication Number Publication Date
EP1292334A1 EP1292334A1 (fr) 2003-03-19
EP1292334A4 true EP1292334A4 (fr) 2003-11-19

Family

ID=22794334

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01939954A Withdrawn EP1292334A4 (fr) 2000-06-22 2001-06-04 Proteine de fusion bispecifique et son procede d'utilisation permettant d'ameliorer l'action tueuse de cellules effectives sur des cellules cibles

Country Status (5)

Country Link
EP (1) EP1292334A4 (fr)
JP (1) JP2003535908A (fr)
AU (2) AU2001265418B2 (fr)
CA (1) CA2412901A1 (fr)
WO (1) WO2001097844A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106065033A (zh) * 2016-03-17 2016-11-02 中国药科大学 一种细胞因子融合抗体的制备及其应用

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI248365B (en) 1999-08-23 2006-02-01 Chugai Pharmaceutical Co Ltd HM1.24 antigen expression potentiators
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
WO2006089133A2 (fr) * 2005-02-15 2006-08-24 Duke University Anticorps anti-cd19 et leur utilisation en oncologie
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
AU2009233925B2 (en) * 2006-12-05 2014-03-13 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
KR101661770B1 (ko) * 2007-09-21 2016-10-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함
US20130058921A1 (en) * 2009-10-30 2013-03-07 Frits VAN RHEE Use of autologous effector cells and antibodies for treatment of multiple myeloma
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
WO2014089354A1 (fr) 2012-12-07 2014-06-12 The Regents Of The University Of California Interféron ciblant l'antigène cd138 présentant de puissantes activités apoptotiques et anti-tumorales
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
ES2774976T3 (es) * 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
WO2014194100A1 (fr) 2013-05-29 2014-12-04 The Regents Of The University Of California Fusions anti-cspg4 et interféron utilisables en vue du traitement de tumeurs malignes
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
MY192918A (en) 2014-09-09 2022-09-15 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
EP3227338A4 (fr) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anticorps anti-cd38 pour le traitement de la leucémie aiguë myéloïde
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL303543A (en) 2015-02-18 2023-08-01 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN113106053A (zh) 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
MY192978A (en) 2015-06-22 2022-09-20 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CA3002674A1 (fr) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions et methodes pour le du traitement du cancer
MX2018005348A (es) 2015-10-30 2018-08-14 Aleta Biotherapeutics Inc Composiciones y metodos para transduccion de tumores.
PL3827845T3 (pl) 2015-11-03 2022-07-11 Janssen Biotech, Inc. Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EP3416661A4 (fr) 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. Association d'une immunothérapie et d'une thérapie de contrôle des cytokines pour le traitement du cancer
AU2017250029C1 (en) * 2016-04-15 2022-03-24 Pfizer Inc. Macrophage stimulation in CD47 blockade therapy
EP3487522A4 (fr) 2016-07-19 2020-04-01 Teva Pharmaceuticals Australia Pty Ltd Polythérapie anti-cd47
CA3070230A1 (fr) * 2017-07-24 2019-01-31 Rutgers, The State University Of New Jersey Molecules de fusion ciblant la phosphatidylserine et leurs procedes d'utilisation
CA3079242A1 (fr) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methodes de traitement du myelome multiple a haut risque
JP6648171B2 (ja) * 2018-02-02 2020-02-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗cd38抗体及び弱毒化インターフェロンアルファ−2bとの融合物
BR112020015202A2 (pt) * 2018-03-01 2020-12-29 Glycotope Gmbh Construções de proteínas de fusão compreendendo um anticorpo anti-muc1 e il-15
AU2020398327A1 (en) 2019-12-03 2022-07-14 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
JP6853392B2 (ja) * 2020-01-15 2021-03-31 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗cd38抗体及び弱毒化インターフェロンアルファ−2bとの融合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396387A2 (fr) * 1989-05-05 1990-11-07 Research Development Foundation Nouveau système de délivrance comportant un anticorps pour les modificateurs de la réponse biologique
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5776456A (en) * 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396387A2 (fr) * 1989-05-05 1990-11-07 Research Development Foundation Nouveau système de délivrance comportant un anticorps pour les modificateurs de la réponse biologique
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5776456A (en) * 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5843439A (en) * 1992-11-13 1998-12-01 Anderson; Darrell R. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
OZZELLO L ET AL: "CONJUGATION OF INTERFERON ALPHA TO A HUMANIZED MONOCLONAL ANTIBODY (HUBRE-3VL) ENHANCES THE SELECTIVE LOCALIZATION AND ANTITUMOR EFFECTS OF INTERFERON IN BREAST CANCER XENOGRAFTS", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 48, no. 2, 1998, pages 135 - 147, XP000940608, ISSN: 0167-6806 *
OZZELLO L ET AL: "EXPERIMENTAL IMMUNOTHERAPY OF BREAST CANCER USING ALPHA INTERFERON CONJUGATED TO MONOCLONAL ANTIBODY MC5", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 353, 1994, pages 35 - 46, XP000940596, ISSN: 0065-2598 *
PALLELA V R ET AL: "INTERFERON-ALPHA-2B IMMUNOCONJUGATE FOR IMPROVING IMMUNOSCINTIGRAPHY AND IMMUNOTHERAPY", JOURNAL OF NUCLEAR MEDICINE, SOCIETY OF NUCLEAR MEDICINE. NEW YORK, US, vol. 41, no. 6, June 2000 (2000-06-01), pages 1108 - 1113, XP000940586, ISSN: 0161-5505 *
See also references of WO0197844A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106065033A (zh) * 2016-03-17 2016-11-02 中国药科大学 一种细胞因子融合抗体的制备及其应用

Also Published As

Publication number Publication date
JP2003535908A (ja) 2003-12-02
EP1292334A1 (fr) 2003-03-19
AU6541801A (en) 2002-01-02
CA2412901A1 (fr) 2001-12-27
WO2001097844A1 (fr) 2001-12-27
AU2001265418B2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
AU6541801A (en) Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
IL153906A0 (en) Method for direct genetic analysis of target cells
IL213109A0 (en) Method of collecting placental stem cells
IL207008A (en) Tissues that have undergone cellular or synthetic tissue containing human placental stem cells and methods for their preparation
IL149802A0 (en) Method of cryopreserving selected sperm cells
GB2390221B (en) Ion beam charge neutralizer and method therefor
AU3064799A (en) Ion mobility storage trap and method
AU2002360540A1 (en) Method for intracellular modifications within living cells using pulsed electric fields
AU2786100A (en) Method of selecting transformed cells and tissues
AU9109001A (en) Method for use of IGF-binding protein for selective sensitization of target cells in vivo
EP1368029A4 (fr) Procede et composition de rajeunissement des cellules, des tissus, des organes, des cheveux et des ongles
AU2002309989A1 (en) Directed evolution of protein in mammalian cells
AU1417701A (en) Soluble t cell receptor protein and method of constructing the same
AU8848998A (en) Insect sequences for improving the efficiency of secretion of non-secreted proteins in eukaryotic cells
AU2001289603A1 (en) Methods and means for the complementation of viral protein expression in stable cell lines
AU2002213954A1 (en) Method for the selective modification of peptides and proteins
AU2003264075A8 (en) Active fusion proteins and method for the production thereof
AU2003229484A1 (en) Device and method for cultivating tissue cells
AU2001236064A1 (en) Method for analysis of substances in tissue or in cells
AU2002333706A1 (en) Method and means for modulating plant cell cycle proteins and their use in plant cell growth control
HUP0102697A3 (en) Method of making proteins in transformed yeast cells
AU2001250585A1 (en) Insecticidal peptides and methods for using same
AU2001267612A1 (en) Method for conditionally immortalising cells and protein constructs therefor
HK1069115A (en) Method for use of igf-binding protein for selective sensitization of target cells in vivo
AU2354501A (en) A new method for the examination of protein localization in living cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 39/395 B

Ipc: 7C 07K 19/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20031002

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

17Q First examination report despatched

Effective date: 20050228

17Q First examination report despatched

Effective date: 20050228

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090723